文献速递前列腺癌

避免不必要活检:PRIMARY评分联合前列腺特异性抗原密度用于前列腺活检决策

Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-12-30

该回顾性单中心研究纳入343例活检前接受68Ga-PSMA PET/CT和MRI、PSA<20 ng/ml的患者,比较PRIMARY评分或PI-RADS联合PSAD的活检策略。决策曲线分析显示PRIMARY+PSAD策略在8-20%风险阈值下净获益高于PI-RADS+PSAD,最佳策略(PRIMARY 4-5或PSAD≥0.20)避免38.2%活检但漏诊9.2% csPCa。

要点

  • PRIMARY评分+PSAD策略在8-20%风险阈值下净获益高于PI-RADS+PSAD策略。
  • 策略#1(PRIMARY 4-5或PSAD≥0.20)避免38.2%活检,漏诊9.2% csPCa。
  • 策略#6(PRIMARY≥3或PSAD≥0.15)避免20.7%活检,漏诊仅3.5% csPCa。

核心结论

  • PRIMARY评分联合PSAD可实现个体化决策以避免不必要活检,优于PI-RADS联合PSAD策略。
  • 需进一步前瞻性试验验证这些发现。

研究设计与样本

  • 回顾性分析343例活检前同时接受68Ga-PSMA PET/CT和MRI的患者,PSA限制为<20 ng/ml。

主要发现

  • csPCa患病率为41.1%(141/343)。
  • 根据决策曲线分析,PRIMARY评分+PSAD策略(策略#1、#2、#6)在8-20%风险阈值下净获益高于PI-RADS+PSAD策略。
  • 最佳诊断策略为策略#1(PRIMARY评分4-5或PSAD≥0.20),避免38.2%活检操作,漏诊9.2% csPCa病例。
  • 从临床角度,漏诊csPCa风险较低的策略为策略#2(PRIMARY评分≥4或PSAD≥0.15),避免28.6%活检,漏诊5.7% csPCa病例。
  • 策略#6(PRIMARY评分≥3或PSAD≥0.15)避免20.7%活检,漏诊仅3.5% csPCa病例。

关键数值与推荐

  • 策略#1:PRIMARY评分4-5或PSAD≥0.20,避免38.2%活检,漏诊9.2% csPCa。
  • 策略#2:PRIMARY评分≥4或PSAD≥0.15,避免28.6%活检,漏诊5.7% csPCa。
  • 策略#6:PRIMARY评分≥3或PSAD≥0.15,避免20.7%活检,漏诊3.5% csPCa。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性为回顾性单中心性质。
  • 需进一步前瞻性试验验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Avoiding unnecessary biopsies for men with suspected prostate cancer remains a clinical priority. The recently proposed PRIMARY score improves diagnostic accuracy in detecting clinically significant prostate cancer (csPCa). The aim of this study was to determine the best strategy combining PRIMARY score or MRI reporting scores (Prostate Imaging Reporting and Data System [PI-RADS]) with prostate-specific antigen density (PSAD) for prostate biopsy decision making. METHODS: A retrospective analysis of 343 patients who underwent both 68Ga-PSMA PET/CT and MRI before prostate biopsy was performed. PSA was restricted to <20 ng/ml. Different biopsy strategies were developed and compared based on PRIMARY score or PI-RADS with PSAD thresholds. Decision curve analysis (DCA) was plotted to define the optimal biopsy strategy. RESULTS: The prevalence of csPCa was 41.1% (141/343). According to DCA, the strategies of PRIMARY score +PSAD (strategy #1, strategy #2, strategy #6) had a higher net benefit than the strategies of PI-RADS + PSAD at the risk threshold of 8-20%. The best diagnostic strategy was strategy #1 (PRIMARY score 4-5 or PSAD ≥ 0.20), which avoided 38.2% biopsy procedures while missed 9.2% of csPCa cases. From a clinical perspective, strategies with a lower risk of missing csPCa were strategy #2 (PRIMARY score ≥4 or PSAD ≥ 0.15), which avoided 28.6% biopsies while missed 5.7% of csPCa cases, or strategy #6 (PRIMARY score≥3 or PSAD ≥ 0.15), which avoided 20.7% biopsies while missed only 3.5% of csPCa cases. The limitations of the study were the retrospective single-center nature. CONCLUSIONS: The combination of PRIMARY score +PSAD allows individualized decisions to avoid unnecessary biopsy, outperforming the strategies of PI-RADS + PSAD. Further prospective trials are needed to validate these findings.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Guo S, Zhang J, Wang Y, et al. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision. Prostate Cancer Prostatic Dis. 2023. PMID: 38160227. doi:10.1038/s41391-023-00782-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。